Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AAV-mediated gene therapy

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: UCB Pharma S.A.

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration November 12, 2020

            Details:

            New collaboration with Lacerta Therapeutics underlines UCB’s strategic focus in gene therapy to fulfil its Patient Value Ambition. New R&D collaboration with Lacerta Therapeutics provides access to a novel gene therapy program and proprietary AAV capsids.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Bristol-Myers Squibb

            Deal Size: $2,100.0 million Upfront Cash: $50.0 million

            Deal Type: Collaboration October 28, 2020

            Details:

            Insitro will apply its proprietary platform, the insitro Human (ISH) platform, to create induced pluripotent stem cell (iPSC) derived disease models for ALS and FTD. BMS will be responsible for clinical development and regulatory submissions and commercialization activities.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Bristol-Myers Squibb

            Deal Size: $2,150.0 million Upfront Cash: $50.0 million

            Deal Type: Collaboration October 28, 2020

            Details:

            insitro will apply insitro Human (ISH) platform, to create induced pluripotent stem cell (iPSC) derived disease models for ALS and FTD. BMS will have the option to select a number of targets identified by insitro to advance through clinical development and commercialization.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: $8.0 million Upfront Cash: Undisclosed

            Deal Type: Funding October 08, 2020

            Details:

            Knopp has developed a discovery platform of molecules directed to a non-opioid biological target linked to chronic pain caused by nerves damage. The drug target is Kv7.2/7.3 which regulates the flow of electrically charged ions required to modulate the excitability of cells.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antibody therapeutics

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Casdin Capital

            Deal Size: $25.5 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing September 29, 2020

            Details:

            The Series A Financing positions the company for rapid scaling of its novel platform and advancing its portfolio of innovative antibody therapeutics for veterinary use.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Boehringer Ingelheim Venture Fund

            Deal Size: $29.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing September 23, 2020

            Details:

            The company’s therapeutic platform is uniquely positioned to discover and develop novel small molecule drugs that can both increase autophagy to more rapidly clear toxic proteins and attenuate the production of neurotoxic proteins.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mitochondria therapy

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Axil Capital Partners

            Deal Size: $9.8 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing September 01, 2020

            Details:

            LUCA Science is developing an innovative platform of highly functional mitochondrial using proprietary technologies. LUCA Science’s mitochondria can be stored and delivered as a biopharmaceutical agent.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ADX10061

            Therapeutic Area: Neurology Product Name: ADX10061

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Innosuisse

            Deal Size: $0.6 million Upfront Cash: Undisclosed

            Deal Type: Funding August 27, 2020

            Details:

            CHF600K Innosuisse grant will support SIB's computational approaches to identify new therapeutic indications for ADX10061, a potent and selective dopamine D1 receptor antagonist.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: The Column Group

            Deal Size: $73.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing July 29, 2020

            Details:

            Nura Bio seeks to alter the course of neurological disease by targeting the fundamental pathways underlying axon degeneration and neuroimmune regulation to preserve neuronal integrity.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Orexia Limited

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 22, 2020

            Details:

            After successfully reaching this development milestone in the collaboration, Orexia exercised an option to exclusively license the orexin receptor type 2 (OX2R) program from X-Chem, which comprises multiple novel OX2R-specific small molecule orexin positive modulators.